These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 29025977

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects.
    Sako Y, Kurimoto E, Mandai T, Suzuki A, Tanaka M, Suzuki M, Shimizu Y, Yamada M, Kimura H.
    Neuropsychopharmacology; 2019 Apr; 44(5):950-960. PubMed ID: 30089885
    [Abstract] [Full Text] [Related]

  • 5. 4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M1 Muscarinic Acetylcholine Receptor.
    Mistry SN, Jörg M, Lim H, Vinh NB, Sexton PM, Capuano B, Christopoulos A, Lane JR, Scammells PJ.
    J Med Chem; 2016 Jan 14; 59(1):388-409. PubMed ID: 26624844
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Therapeutic potential of TAK-071, a muscarinic M1 receptor positive allosteric modulator with low cooperativity, for the treatment of cognitive deficits and negative symptoms associated with schizophrenia.
    Kurimoto E, Yamada R, Hirakawa T, Kimura H.
    Neurosci Lett; 2021 Nov 01; 764():136240. PubMed ID: 34509568
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor.
    Mistry SN, Valant C, Sexton PM, Capuano B, Christopoulos A, Scammells PJ.
    J Med Chem; 2013 Jun 27; 56(12):5151-72. PubMed ID: 23718562
    [Abstract] [Full Text] [Related]

  • 9. M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition.
    Moran SP, Dickerson JW, Cho HP, Xiang Z, Maksymetz J, Remke DH, Lv X, Doyle CA, Rajan DH, Niswender CM, Engers DW, Lindsley CW, Rook JM, Conn PJ.
    Neuropsychopharmacology; 2018 Jul 27; 43(8):1763-1771. PubMed ID: 29581537
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor.
    Abdul-Ridha A, Lane JR, Mistry SN, López L, Sexton PM, Scammells PJ, Christopoulos A, Canals M.
    J Biol Chem; 2014 Nov 28; 289(48):33701-11. PubMed ID: 25326383
    [Abstract] [Full Text] [Related]

  • 14. Design and Synthesis of γ- and δ-Lactam M1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M1-Selective PAM with Weak Agonist Activity.
    Davoren JE, Garnsey M, Pettersen B, Brodney MA, Edgerton JR, Fortin JP, Grimwood S, Harris AR, Jenkinson S, Kenakin T, Lazzaro JT, Lee CW, Lotarski SM, Nottebaum L, O'Neil SV, Popiolek M, Ramsey S, Steyn SJ, Thorn CA, Zhang L, Webb D.
    J Med Chem; 2017 Aug 10; 60(15):6649-6663. PubMed ID: 28598634
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterization of a Novel M1 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator Radioligand, [3H]PT-1284.
    Smith DL, Davoren JE, Edgerton JR, Lazzaro JT, Lee CW, Neal S, Zhang L, Grimwood S.
    Mol Pharmacol; 2016 Sep 10; 90(3):177-87. PubMed ID: 27382013
    [Abstract] [Full Text] [Related]

  • 17. AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model.
    Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D, Friberg M, Burstein ES, Spalding TA, Ott TR, Schiffer HH, Tabatabaei A, McFarland K, Davis RE, Bonhaus DW.
    Neuropharmacology; 2010 Feb 10; 58(2):365-73. PubMed ID: 19835892
    [Abstract] [Full Text] [Related]

  • 18. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M1 Receptor, and Xanomeline, an Agonist of Muscarinic M1/M4 Receptor, in Rodents.
    Mandai T, Kasahara M, Kurimoto E, Tanaka M, Suzuki M, Nakatani A, Kimura H.
    Neuroscience; 2019 Aug 21; 414():60-76. PubMed ID: 31299348
    [Abstract] [Full Text] [Related]

  • 19. Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M1 Muscarinic Acetylcholine Receptors.
    van der Westhuizen ET, Spathis A, Khajehali E, Jörg M, Mistry SN, Capuano B, Tobin AB, Sexton PM, Scammells PJ, Valant C, Christopoulos A.
    Mol Pharmacol; 2018 Jul 21; 94(1):770-783. PubMed ID: 29691279
    [Abstract] [Full Text] [Related]

  • 20. Using cholinergic M1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communication.
    Chambon C, Jatzke C, Wegener N, Gravius A, Danysz W.
    Eur J Pharmacol; 2012 Dec 15; 697(1-3):73-80. PubMed ID: 23085025
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.